The Research Question Alka M. Kanaya, MD Associate Professor of Medicine, Epidemiology & Biostatistics UCSF October 3, 2011.

Slides:



Advertisements
Similar presentations
Summary Prepared by Melvyn Rubenfire, MD
Advertisements

Cardio-Metabolic Syndrome Guidelines on Education, Detection and Early Treatment  Heval Mohamed Kelli, PGY-2 Emory Internal Medicine Residency no conflict.
SUPERSIZED NATION By Jennifer Ericksen August 24, 2007.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States Ian H. de Boer, MD, MS, Tessa C. Rue, MS, Yoshio N. Hall, MD, Patrick.
CVD risk estimation and prevention: An overview of SIGN 97.
OBESITY and CHD Nathan Wong. OBESITY AHA and NIH have recognized obesity as a major modifiable risk factor for CHD Obesity is a risk factor for development.
Presenter Disclosure Information Paul M Ridker, MD, FACC Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women’s Hospital that.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Slide Source: Lipids Online Slide Library Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.
Epi 202:Designing Clinical Research Session 1: Introduction to the Course and to Clinical Research Thomas B. Newman, MD,MPH Professor of Epidemiology &
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Building a research career on ancillary studies Kirsten Bibbins-Domingo, PhD, MD Associate Professor of Medicine and of Epidemiology and Biostatistics.
Effectiveness of interactive web-based lifestyle program on prevention of cardiovascular diseases risk factors in patient with metabolic syndrome: a randomized.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
LIFESTYLE MODIFICATIONS FOR PREVENTING HEART DISEASE [e.g. HEART ATTACKS] [ primary prevention of coronary artery disease ] DR S. SAHAI MD [Med.], DM [Card]
Introduction to the course and to your assignment
Body Mass Index, Weight Change and Death in an Older Hypertensive Population: The SHEP Study Grant W Somes Stephen B Kritchevsky Marco Pahor Ronald I Shorr.
Population Impact Measures (PIM)
Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Heart Health Project University of Pennsylvania School of Medicine American Heart Association Pennsylvania State University Funded by the Robert Wood Johnson.
Low level of high density lipoprotein cholesterol in children of patients with premature coronary heart disease. Relation to own and parental characteristics.
Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.
Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes The TODAY clinical trial Featured Article: TODAY Study Group* Diabetes Care Volume.
Metabolic Syndrome Yusra Mir, MD Zunairah Syed, MD Harjagjit Maan, MD.
Introduction to Clinical Research and Research Questions Thomas B. Newman, MD,MPH Professor of Epidemiology & Biostatistics and Pediatrics, UCSF Epi ,
VA/DoD 2006 Clinical Practice Guideline For Screening and Management of Overweight and Obesity Guideline Summary: Key Elements.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Organizational criteria for Metabolic Syndrome National Cholesterol Education Program Adult Treatment Panel III World Health OrganizationAmerican Association.
Ethnic variation in the contribution of Cardiorespiratory fitness and muscular strength to diabetes: crossectional study of 68,116 UK Biobank participants.
Diabetes Centre Hippokration Hospital Athens, Greece B. KARAMANOS 2007 Report of he MGSD Nutrition Study B. Karamanos MD Associate Professor of Medicine.
Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP
Department of Epidemiology and Biostatistics DESIGNING CLINICAL RESEARCH Session #1 About this course Chapters 1 & 2 Examples.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Critical Appraisal Articles about Therapy or Prevention Jeffrey P Schaefer MSc MD FRCPC March 26, 2007.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Prevention of Diabetes Mellitus Prof. Adel El-Etriby Professor of Cardiology Ain Shams Faculty of Medicine.
A Diabetes Outcome Progression Trial
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
END Obesity Dr Gul Bano © S Nussey. What is obesity?
Thiazide diuretics, Potassium, and the Development of Diabetes A Quantitative Review Hypertension2006_219.
Dr. I. Selvaraj Indian Railways Medical Service B.Sc., M.B.B.S., M.D.,D.P.H., D.I.H., PGCHFW ( NIHFW,New Delhi)., Life member of Indian Association of.
Diabetes Prevention Program (DPP)
Baseline Prevalence of Metabolic Syndrome and Individual Components Among 4258 Older Adults Dariush Mozaffarian, et al. Arch Intern Med. 2008;168:
Chapter 14 Patterns in Health and Disease: Epidemiology and Physiology EXERCISE PHYSIOLOGY Theory and Application to Fitness and Performance, 6th edition.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Scott W. Rypkema, M.D.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
 In 2003, the USPSTF recommended that clinicians screen adults for obesity and offer intensive counseling and behavioral interventions to promote weight.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
The Metabolic Syndrome in a State Psychiatric Hospital Population Although studies of Metabolic Syndrome (MetS) have been conducted in private and community.
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
Circulation. 2014;129: Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy.
Yusra Mir, MD Zunairah Syed, MD Harjagjit Maan, MD
The ACCORD Trial: Review of Design and Results
ACCORD Design and Baseline Characteristics
The Anglo Scandinavian Cardiac Outcomes Trial
Management of Type II Diabetes
Systolic Blood Pressure Intervention Trial (SPRINT)
Exercise and adult women’s health
Section overview: Cardiometabolic risk reduction
Potential mechanisms whereby statins may reduce the risk of stroke
Goals & Guidelines A summary of international guidelines for CHD
What is Rippe Lifestyle institute?
Presentation transcript:

The Research Question Alka M. Kanaya, MD Associate Professor of Medicine, Epidemiology & Biostatistics UCSF October 3, 2011

Anatomy of research: What it’s made of n Research question –significance n Study design n Study participants: –The target population –The study population (and how they will be sampled) n Variables (and how they will be measured) –Predictor –Outcome n Analysis plan, sample size calculation

NIH Roadmap Initiative -translating discoveries into health Westfall JM et al, JAMA 2007

Translational Research and Studies for this course n Not the best choice for this course: –Animals, molecules without humans –Data syntheses, e.g. decision analysis, cost- effectiveness analysis, meta-analysis –Qualitative research n Ideal –An observational study involving humans that you could do in limited time as a resident (secondary data analysis of an existing database)

Secondary data analysis n Rethink the decisions that were already made and getting thoughts and suggestions for colleagues n Design a new study you aren’t (currently) planning to do

Physiology of research: How it works Using measurements in a sample to draw inferences about phenomena in a population

DCR Figure 1.3

DCR Figure 1.4

DCR Figure 1.5

My preliminary research question n Is HRT associated with diabetes? n Is postmenopausal HRT use associated with lower incidence of diabetes?

Background n Effect of hormone therapy on glucose: –RCT evidence: variable –Observational studies: consistent benefit n Effect of hormone therapy on diabetes incidence: –Observational studies: variable –No RCT has evaluated this outcome

Specify the Study Design n Observational study –Cohort –Cross-sectional –Cohort –Case control n Randomized clinical trial –Surrogate endpoints –Endpoints of primary interest n Importance of thorough literature review and scholarship

Does the Research Question meet the FINER criteria? F easible I nteresting N ovel E thical R elevant

Cohort Design n Subjects: participants of a large cohort (Nurses Health Study) n Predictor: HRT use n Outcome: incidence of diabetes

Cross-sectional design n Subjects: large sample of postmeno- pausal women n Predictor: HRT use n Outcome: Diabetes (prevalent)

Case-control design n Subjects: –Cases: 100 women with diabetes –Controls: 100 adults selected from same population setting, without diabetes n Predictor: HRT use n Outcome: cases vs. controls

Randomized blinded trial design: Surrogate outcomes n Subjects: 1,000 postmenopausal women n Predictor: –randomized to HRT vs. placebo n Outcome: 1 year later –Change in fasting glucose levels

Randomized blinded trial design: Disease event outcomes n Subjects: 2,700 postmenopausal women n Predictor: –randomized to HRT vs. placebo n Outcome: 4 years later –Incidence of type 2 diabetes

Effect of HRT on Fasting Glucose (HERS post-hoc analysis)

4 year Incidence of Diabetes * % Inclusive Defn. Glucose  126 alone * p  0.05 * * *

NNT To prevent one case of incident diabetes: 31

Risk of Incident Diabetes * adjusted for age, race, education, alcohol, smoking, physical activity, BMI, waist circumference, TG, HDL, HTN, use of diuretics, B-blockers, ACE inhibitors, and statins Kanaya, Annals Int Med, 2003

My next research question n Does yoga improve the metabolic syndrome (waist circumference, blood pressure, glucose, lipids)? n Does yoga prevent/delay type 2 diabetes?

Proven Methods to Prevent T2DM n Intensive lifestyle change –Weight loss, exercise, healthier diet n Medications: –Metformin –Rosiglitazone –Acarbose –Orlistat n Other non-pharmacologic methods?

Why Yoga? n Systematic review—small trials with benefit –BP reduction in hypertensive patients –Glucose reduction in diabetes patients –Cholesterol lowering in CHD patients Yoga ↓ Stress ↓ Visceral fat Improve Met. Syn ↓ Glucose ↓ BP Improve lipids ↑ Sleep

Does the Research Question meet the FINER criteria? F easible I nteresting N ovel E thical R elevant

Add “G”: G ood for your career Try to identify a research question that will allow you to –Learn more about an area of potential long-term interest – Acquire new skills you could use on other projects –Work with people and/or organizations with whom you want to develop a long term relationship –Build on the project for future work

Cohort Design n Subjects: Nurses Health Study- that includes questions about yoga practice, lab measures; (no waist circumference); n Predictor: yoga practice (frequency) n Outcome: incidence of the metabolic syndrome (or individual components); incidence of type 2 diabetes in future visits

Cross-sectional design n Subjects: CHIS survey that includes questions about yoga practice, lab measures, at one time-point n Predictor: yoga practice (frequency) n Outcome: metabolic syndrome; diabetes (prevalence)

Case-control design n Subjects: –Cases: 100 adults with the metabolic syndrome –Controls: 100 adults without the metabolic syndrome n Predictor: practice yoga? n Outcome: cases vs. controls

Randomized blinded trial design: Surrogate outcomes n Subjects: 180 adults with the metabolic syndrome n Predictor: –randomized to yoga vs. stretch intervention n Outcome: 1 year later –Change in metabolic syndrome (each components)

Randomized blinded trial design: Disease event outcomes n Subjects: adults with the metabolic syndrome n Predictor: –randomized to yoga vs. stretch intervention n Outcome: 3-5 years later –Incidence of type 2 diabetes

Does the Research Question meet the FINER criteria? F easible I nteresting N ovel E thical R elevant

The research cycle Develop research question Design study Implement study Analyze results Infer conclusions

One sentence describing anatomy of your study n Research question n Design n Subjects n Variables –Predictor –Outcome

Do you have a FINER research question? F easible I nteresting N ovel E thical R elevant

Funded by K23 HL and a UCSF REAC grant